Skip to main content
OpenTrials
Completed

NCT Number: NCT03770078

Assessment of New Enhanced Ostomy Device in Real-life Settings in Subjects Having a Stoma

The study investigates the performance of a new adhesive with regard to the skin condition

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CCBR Aalborg, Aalborg, Denmark

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have given written informed consent
  • Have an ileostomy or a colostomy with liquid* output (as their usual output)
  • Be at least 18 years of age and have full legal capacity
  • Have had their stoma for at least three months
  • Be able to use products with max cut size 45 mm
  • Have self-reported problems with leakage** (three times within 14 days)
  • Handle the Clinical App, test product and comparator product themselves
  • Use a flat SenSura® Mio or a flat SenSura® with standard adhesive as their current product
  • Minimum change of baseplate at least once every 3rd day
  • Are willing and suitable (determined by investigator/study nurse) to use the test product and comparator without using a paste/mouldable ring during the investigation
  • Are willing and suitable (determined by investigator/study nurse) to use a 1-piece product during the investigation

Exclusion criteria

  • Are currently receiving or have within the past two months received radio-and/or chemotherapy (low doses chemotherapy are allowed for other indications than cancer, e.g. below 15 mg methotrexate for rheumatoid arthritis)
  • Are currently receiving or have within the past month received topical steroid treatment in the peristomal skin area (e.g. lotion or spray) or systemic treatment* (e.g. injection or tablets).
  • Get a positive result of a pregnancy test for women of childbearing age/fertile (**clarified in section 6.3.2)
  • Are breast feeding
  • Are participating in other interventional clinical investigations or have previously participated in this investigation

Exception:

Participation in other Coloplast in-house clinical investigations is accepted under the circumstances that the subject has paused the activities in the investigation and are otherwise complying with the inclusion and exclusion criteria of this (CP300) protocol.

  • Have known hypersensitivity towards any of the products used in the investigation

Treatment and study plan

Test Product A

Device

The test product is a newly developed ostomy product

Primary outcomes

  1. Trans Epidermal Water Loss

    Time frame: Four weeks

    Trans epidermal water loss is an objective skin measurement that is measures the evaporation of water on the skin surface using a probe (DermaLab).The trans epidermal water loss is a measure for the skins barrier function. There is always a loss of water from the skin due to evaporation. When the skin barrier is damaged this evaporation of water increases. Thus, transepidermal water loss can be used to assess skin damage.

    Trans Epidermal Water Loss is reported in grams of water per square meter per hour (g/m^2/h).

Sponsors and collaborators

Lead sponsor

Coloplast A/S

Industry

Registry information

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Dec 10, 2018
Registry last updated
Apr 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.